Abstracts tagged "Tofacitinib"

Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Paul Bird¹, Geoffrey Littlejohn ², Belinda Butcher ³, Tegan Smith ⁴, Candida da Fonseca Pereira ⁵, David Witcombe ⁵ and Hedley Griffiths ⁶, ¹Optimus Research, Kogarah, New South Wales, Australia, ²Monash Rheumatology, Clayton, Victoria, Australia, ³WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁴OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, ⁵Pfizer Australia, Sydney, New South Wales, Australia, ⁶Barwon Rheumatology Service, Geelong, Victoria, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
Abstract Number: L09 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
Rishi J. Desai¹, Ajinkya Pawar², Michael E Weinblatt³ and Seoyoung C. Kim⁴, ¹Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: A potentially increased risk of venous thromboembolism (VTE) was noted in pre-marketing trials of baricitinib, which is a Janus kinase inhibitor (JAK-I). This led…
Abstract Number: 522 • 2017 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Sander Strengholt⁶, Ryan DeMasi⁷ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here, we report tofacitinib safety and tolerability up to 114…
Abstract Number: 1609 • 2016 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials
Stephen Hall¹, Peter Nash², Maureen Rischmueller³, Zirke Wiid⁴, David Witcombe⁵, David Gruben⁶, Ryan DeMasi⁷ and Tatjana Lukic⁷, ¹Cabrini Medical Centre, Monash University, Melbourne, Australia, ²University of Queensland, Brisbane, Australia, ³The Queen Elizabeth Hospital, Adelaide, Australia, ⁴Pfizer Australia, Sydney, Australia, ⁵Pfizer Australia, Sydney, NSW, Australia, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc analysis of data from Phase 3 studies investigated the efficacy…
Abstract Number: 3024 • 2016 ACR/ARHP Annual Meeting
Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
Christina Charles-Schoeman¹, Hernan Valdez², Koshika Soma², Lie-Ju Hwang², Ryan DeMasi², Mary Boy³ and Iain B McInnes⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, New York, NY, ³Pfizer Inc, Groton, CT, ⁴Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: RA patients (pts) are at increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].